TAT-RasGAP317-326 requires p53 and PUMA to sensitize tumor cells to genotoxins

Molecular Cancer Research

Volumn 5, Issue 5, 2007, Pages 497-507

  Michod, David ^a   Widmann, Christian ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; TRANSACTIVATOR PROTEIN; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MUTAGENIC AGENT; ONCOPROTEIN; PEPTIDE; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER CELL; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE CONTROL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; CELL STRAIN HCT116; CHEMISTRY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THERMODYNAMICS; TUMOR CELL LINE;

ACETYLATION; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE PRODUCTS, TAT; HCT116 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTAGENS; NEOPLASMS; PEPTIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS GTPASE-ACTIVATING PROTEINS; THERMODYNAMICS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34250210700     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0257     Document Type: Article

References (44)

1. Chabner BA, Roberts TG, Jr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:65-72.
2. Widmann C, Gibson S, Johnson GL. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J Biol Chem 1998;273:7141-7.
3. Wen LP, Madani K, Martin GA, Rosen GD. Proteolytic cleavage of Ras GTPase-activating protein during apoptosis. Cell Death Differ 1998;5:729-34.
4. Yang J-Y, Widmann C. Antiapoptotic signaling generated by caspase-induced cleavage of RasGAP. Mol Cell Biol 2001;21:5346-58.
5. Yang J-Y, Michod D, Walicki J, et al. Partial cleavage of RasGAP by caspases is required for cell survival in mild stress conditions. Mol Cell Biol 2004;24: 10425-36.
6. Yang J-Y, Walicki J, Abderrahmani A, et al. Expression of an uncleavable N-terminal RasGAP fragment in insulin-secreting cells increases their resistance toward apoptotic stimuli without affecting their glucose-induced insulin secretion. J Biol Chem 2005;280:32835-42.
7. Michod D, Yang JY, Chen J, Bonny C, Widmann C. A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells. Oncogene 2004;23:8971-8.
8. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-808.
9. Zabkiewicz J, Clarke AR. DNA damage-induced apoptosis: insights from the mouse. Biochim Biophys Acta 2004;1705:17-25.
10. Michalak E, Villunger A, Erlacher M, Strasser A. Death squads enlisted by the tumour suppressor p53. Biochem Biophys Res Commun 2005;331: 786-98.
11. Kulkarni SV, Gish G, Van der Geer P, Henkemeyer M, Pawson T. Role of p120 ras-GAP in directed cell movement. J Cell Biol 2000;149:457-70.
12. Tocque B, Delumeau I, Parker F, Maurier F, Multon MC, Schweighoffer F. Ras-GTPase activating protein (GAP): a putative effector for Ras. Cell Signal 1997;9:153-8.
13. Yang J-Y, Widmann C. The RasGAP N-terminal fragment generated by caspase cleavage protects cells in a Ras/PI3K7Akt-dependent manner that does not rely on NFκB activation. J Biol Chem 2002;277:14641-6.
14. Widmann C, Gibson S, Jarpe MB, Johnson GL. MAPK pathways: conservation of a three-kinase module from yeast to man. Physiol Rev 1999; 79:143-80.
15. Pearson G, Robinson F, Beers GT. et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22: 153-83.
16. Sears RC, Nevins JR. Signaling networks that link cell proliferation and cell fate. J Biol Chem 2002;277:11617-20.
17. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-22.
18. Vousden KH. Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 2002;1602:47-59.
19. 2 arrest after DNA damage. Science 1998;282:1497-501.
20. Saller E, Tom E, Brunori M, et al. Increased apoptosis induction by 121F mutant p53. EMBO J 1999;18:4424-37.
21. Shao RG, Shimizu T, Pommier Y. 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53. Exp Cell Res 1997;234:388-97.
22. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-7.
23. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
24. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
25. Lane DP, Hall PA. MDM2 - arbiter of p53's destruction. Trends Biochem Sci 1998;22:372-4.
26. Li Y, Jenkins CW, Nichols MA, Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994;9: 2261-8.
27. Saito S, Yamaguchi H, Higashimoto Y, et al. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 2003;278:37536-44.
28. Chao C, Herr D, Chun J, Xu Y. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J 2006; 25:2615-22.
29. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793-805.
30. El Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
31. Nijhawan D, Fang M, Traer E, et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003;17: 1475-86.
32. Zhuang J, Brady HJ. Emerging role of Mcl-1 in actively counteracting BH3-only proteins in apoptosis. Cell Death Differ 2006;13:1263-7.
33. Herrant M, Jacquel A, Marchetti S, et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004;23: 7863-73.
34. Michels J, O'Neill JW, Dallman CL, et al. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene 2004;23:4818-27.
35. Clohessy JG, Zhuang J, Brady HJ. Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells. Br J Haematol 2004;125:655-65.
36. Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 2005;280:10491-500.
37. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001;7:673-82.
38. Trahey M, McConnick F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 1987;238:542-5.
39. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005;309:1732-5.
40. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-59.
41. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A 2003;100:1931-6.
42. 1 arrest in human cancer cells. Cancer Res 1995;55:5187-90.
43. Jordan M, Schallhorn A, Wurm FM. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 1996;24:596-601.
44. Kaeser MD, Pebernard S, Iggo RD. Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem 2004;279:7598-605.